Physician profile
David L Chu
NPI 1568617223
$1,991.82
in general payments reported to CMS, 2019-2025
22 companies · $362 in 2025
The $362 reported for 2025 was more than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $145 · 2020: $157 · 2021: $238 · 2022: $397 · 2023: $377 · 2024: $317 · 2025: $362.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,055.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,055.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $753.85 | 2022-2025 | Qulipta, Botox, Ubrelvy |
| Nevro Corp. | $136.39 | 2021 | |
| Si-Bone, INC. | $126.52 | 2020-2025 | |
| Bausch & Lomb Americas INC. | $124.65 | 2023 | Stellaris |
| Pfizer INC. | $120.43 | 2023-2025 | |
| Dompe US, INC. | $117.46 | 2022 | |
| Mallinckrodt Enterprises LLC | $73.59 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $70.25 | 2022-2024 | Ajovy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $55.71 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $53.80 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $43.44 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $43.35 | 2021 | |
| Sun Pharmaceutical Industries INC. | $42.58 | 2025 | |
| Allergan, INC. | $38.09 | 2019-2020 | |
| Axsome Therapeutics, INC. | $31.77 | 2025 | Symbravo |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $29.86 | 2020 | |
| Lilly USA, LLC | $28.54 | 2021-2024 | Emgality |
| Ucb, INC. | $28.45 | 2019 | |
| Nalu Medical, INC. | $24.47 | 2024 | Nalu Neurostimulation System |
| Vertex Pharmaceuticals Incorporated | $16.42 | 2025 | |
| Supernus Pharmaceuticals, INC. | $16.40 | 2021 | |
| Tonix Medicines, INC. | $15.80 | 2025 | Zembrace Symtouch |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Chu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.